Analysis on signal transduction pathway through CD103 molecule

CD103分子信号转导通路分析

• 批准号: 20591193
• 负责人: TAKEUCHI Tsutomu
• 金额: $ 3万
• 依托单位: Saitama Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20591193/
• 关键词: 自己免疫; 上皮障害; カドヘリン; インテグリン; CD103; シグナル伝達; CDIO3

Given the evidence that αEβ7(CD03) expressed on T cells is involved in adhesion with E-cadherin on epithelial cells, the CD103 molecule may play a wide variety role in cellular function. In this study, it has been shown that for induction of CD103, not only the expression of TGF-βreceptor by lectin, but also signal transduction through Smad 2/3 is required. After expression of CD103, T cells become proliferate poor, and exhibit unique cytokine prolife. Since CD103+subset of cells can mediate immune-regulatory and immune- inflammatory function, farther investigation may be regained to dissect thesignal leady to two distinct function.

鉴于T细胞上表达的αEβ7（CD 03）参与与上皮细胞上的E-钙粘蛋白的粘附的证据，CD 103分子可能在细胞功能中发挥广泛的作用。在本研究中，已经表明，为了诱导CD 103，不仅需要通过凝集素表达TGF-β受体，而且还需要通过Smad 2/3进行信号转导。在表达CD 103后，T细胞变得增殖不良，并表现出独特的细胞因子促增殖。由于CD 103+细胞亚群可以介导免疫调节和免疫炎症功能，因此进一步研究可能会重新获得导致两种不同功能的信号。

项目成果

Impact to through serum level on Radiographic and Clinical Response to Infliximab plus Methotrexate in Patients with Rheumatoid Arthriti : results from the RISING Study.

类风湿关节炎患者血清水平对英夫利昔单抗加甲氨蝶呤放射学和临床反应的影响：RISING 研究的结果。

• 发表时间: 2009
• 期刊: Mod Rheumatology 19
• 作者: Takeuchi T;Miyasaka N;Inoue K;Abe T;Koike T
• 通讯作者: Koike T

Long-term safety and efficacy of tocilizumab, an anti-interleuk in(IL)-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis(the STREAM study) : evidence of safety and efficacy in a 5-year extension study.

托珠单抗（一种抗白细胞介素（IL）-6 受体单克隆抗体）在类风湿性关节炎患者单一疗法中的长期安全性和有效性（STREAM 研究）：一项为期 5 年的扩展研究的安全性和有效性证据。

• 发表时间: 2009
• 期刊: Ann Rheum Dis 68
• 作者: Nishimoto N;Miyasaka N;Yamamoto K;Kawai S;Takeuchi T;Azuma J.
• 通讯作者: Azuma J.

The comparison of efficacy and safety between continuation and discontinuation of methotrexate(MTX)at the commencement of etanercept in patients with active rheumatoid arthritis despite MTX therapy : 24-week results from the JESMR study.

尽管接受了 MTX 治疗，但活动性类风湿性关节炎患者在开始依那西普治疗时继续和停止甲氨蝶呤 (MTX) 的疗效和安全性比较：JESMR 研究的 24 周结果。

• 发表时间: 2010
• 期刊: Rheumatology (in press)
• 作者: Kameda H;Ueki Y;Saito K;Nagaoka S;Hidaka T;Atsumi T;Tsukano M;Kasama T;Shiozawa S;Tanaka Y;Takeuchi T;Japan Biological Agent Integrated Consortium(J-BASIC).
• 通讯作者: Japan Biological Agent Integrated Consortium(J-BASIC).

IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialo-adenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation.

IgG4 阳性多器官淋巴增殖综合征，表现为慢性对称性硬化性泪腺炎，随后继发性门脉高压和 IgG4 相关的 IL-4 显着升高。

• 发表时间: 2010
• 期刊: Rheumatology
• 影响因子: 5.5
• 作者: Suzuki K;Tamaru J;Okuyama A;Kameda H;Amano K;Nagasawa H;Nishi;E;Yoshimoto K;Setoyama Y;Kaneko K;Osada H;Honda N;Yasaki Y;Itoyama S;Tsuzaka K;Takeuchi T.
• 通讯作者: Takeuchi T.

免疫難病における新しいターゲット分子と制御

免疫疑难疾病的新靶分子及调控

• 发表时间: 2009
• 作者: Takizawa Y.;Inokuma S.;Tanaka Y.;Saito K.;Atsumi T.;Hirakata M.;Kameda H.;Hirohata S.;Kondo H.;Kumagai S.;Tanaka Y.;出原賢治;竹内勤
• 通讯作者: 竹内勤